Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

USA - NASDAQ:GLSI - US3968791083 - Common Stock

9.21 USD
+0.02 (+0.22%)
Last: 10/31/2025, 8:00:01 PM
9.2 USD
-0.01 (-0.11%)
Pre-Market: 11/3/2025, 4:22:59 AM
Fundamental Rating

1

GLSI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of GLSI is average, but there are quite some concerns on its profitability. GLSI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year GLSI has reported negative net income.
GLSI had a negative operating cash flow in the past year.
GLSI had negative earnings in each of the past 5 years.
In the past 5 years GLSI always reported negative operating cash flow.
GLSI Yearly Net Income VS EBIT VS OCF VS FCFGLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

GLSI has a Return On Assets of -575.74%. This is amonst the worse of the industry: GLSI underperforms 96.82% of its industry peers.
GLSI has a worse Return On Equity (-1249.92%) than 82.02% of its industry peers.
Industry RankSector Rank
ROA -575.74%
ROE -1249.92%
ROIC N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
GLSI Yearly ROA, ROE, ROICGLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLSI Yearly Profit, Operating, Gross MarginsGLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

The number of shares outstanding for GLSI has been increased compared to 1 year ago.
The number of shares outstanding for GLSI has been increased compared to 5 years ago.
There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLSI Yearly Shares OutstandingGLSI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GLSI Yearly Total Debt VS Total AssetsGLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

GLSI has an Altman-Z score of -6.82. This is a bad value and indicates that GLSI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.82, GLSI is doing worse than 66.67% of the companies in the same industry.
There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.82
ROIC/WACCN/A
WACCN/A
GLSI Yearly LT Debt VS Equity VS FCFGLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

GLSI has a Current Ratio of 1.85. This is a normal value and indicates that GLSI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of GLSI (1.85) is worse than 77.72% of its industry peers.
A Quick Ratio of 1.85 indicates that GLSI should not have too much problems paying its short term obligations.
GLSI has a worse Quick ratio (1.85) than 75.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.85
GLSI Yearly Current Assets VS Current LiabilitesGLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

0

3. Growth

3.1 Past

GLSI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.79%.
EPS 1Y (TTM)-70.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -7.71% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.93%
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLSI Yearly Revenue VS EstimatesGLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M
GLSI Yearly EPS VS EstimatesGLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLSI Price Earnings VS Forward Price EarningsGLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLSI Per share dataGLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

GLSI's earnings are expected to decrease with -7.71% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%

0

5. Dividend

5.1 Amount

GLSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (10/31/2025, 8:00:01 PM)

Premarket: 9.2 -0.01 (-0.11%)

9.21

+0.02 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners10.45%
Inst Owner Change0%
Ins Owners53.23%
Ins Owner Change0%
Market Cap125.53M
Revenue(TTM)N/A
Net Income(TTM)-17992600
Analysts82.5
Price Target42.84 (365.15%)
Short Float %21.07%
Short Ratio19.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.34%
Min EPS beat(2)-22.55%
Max EPS beat(2)-2.12%
EPS beat(4)1
Avg EPS beat(4)-50.71%
Min EPS beat(4)-184.78%
Max EPS beat(4)6.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-28.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 87.21
P/tB 87.21
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -575.74%
ROE -1249.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.85
Altman-Z -6.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y6.93%
EPS Next 2Y-12.16%
EPS Next 3Y-7.71%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.28%
OCF growth 3YN/A
OCF growth 5YN/A

GREENWICH LIFESCIENCES INC / GLSI FAQ

What is the fundamental rating for GLSI stock?

ChartMill assigns a fundamental rating of 1 / 10 to GLSI.


What is the valuation status for GLSI stock?

ChartMill assigns a valuation rating of 0 / 10 to GREENWICH LIFESCIENCES INC (GLSI). This can be considered as Overvalued.


What is the profitability of GLSI stock?

GREENWICH LIFESCIENCES INC (GLSI) has a profitability rating of 0 / 10.